<DOC>
	<DOCNO>NCT00014001</DOCNO>
	<brief_summary>The CATIE Schizophrenia Trial part Clinical Antipsychotic Trials Intervention Effectiveness ( CATIE ) Project . The schizophrenia trial conduct determine long-term effect usefulness antipsychotic medication person schizophrenia . It design people schizophrenia may benefit medication change . The study involve new atypical antipsychotic ( olanzapine , quetiapine , risperidone , clozapine , ziprasidone ) typical antipsychotic ( perphenazine fluphenazine decanoate ) . All participant receive initial comprehensive medical psychiatric evaluation closely follow throughout study . For participant study last 18 month . Everyone study offer educational program schizophrenia family member encourage participate .</brief_summary>
	<brief_title>CATIE- Schizophrenia Trial</brief_title>
	<detailed_description>This trial consist 1600 patient schizophrenia medication change may indicate reason limited efficacy tolerability . All patient receive psychosocial treatment study participation . Research participant family member offer psychosocial intervention direct improve patient family understand illness , decrease burden illness family , maximize treatment adherence , minimize relapse , enhance access range community-based rehabilitative service improve study retention . Phase I : Patients randomly assign one five treatment condition 18 month : 1 . 320 begin double-blind treatment perphenazine ( PER ) 2 . 320 begin double-blind treatment olanzapine ( OLZ ) 3 . 320 begin double-blind treatment quetiapine ( QUET ) 4 . 320 begin double-blind treatment risperidone ( RIS ) 5 . 220 begin double-blind treatment ziprasidone ( ZIP ) Phase IA : 100 patient screen found tardive dyskinesia would otherwise eligible study randomly assign one four atypical drug Phase IA . Phase IB : Patients fail treatment perphenazine Phase I randomly assign olanzapine , quetiapine , risperidone Phase IB . Phase II : Patients discontinue initial assigned atypical antipsychotic treatment Phase I , IA , IB non-administrative reason proceed second assign treatment ( third Phase IB patient ) follow remainder 18-month participation , follow : 1 . Patients originally assign one new atypical antipsychotic discontinue due efficacy failure randomly assign double-blind treatment one two new atypical antipsychotic ( OLZ , RIS , QUET ) previously receive ( 50 % ) open label clozapine ( 50 % ) . 2 . Patients originally assign one new atypical antipsychotic discontinue due tolerability failure randomly assign double-blind treatment one new atypical antipsychotic ( OLZ , RIS , QUET ) previously receive ( 50 % ) , ziprasidone ( 50 % ) . Until ziprasidone activate , patient assign one atypical antipsychotic . Phase II last least 6 month , even mean participant stay study 18 month Phase III : Patients discontinue Phase II recommend open treatment prefer regimen base treatment history study . The treatment option include clozapine , new atypical antipsychotic ( olanzapine , risperidone , quetiapine , ziprazidone , aripiprazole ) , fluphenazine decanoate , perphenazine , dual antipsychotic therapy use two drug . Note : All treatment double-blinded treatment Phases I II except clozapine .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Perphenazine</mesh_term>
	<mesh_term>Fluphenazine</mesh_term>
	<mesh_term>Fluphenazine depot</mesh_term>
	<mesh_term>Fluphenazine enanthate</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Inclusion 1865 year old DSMIV diagnosis schizophrenia adequate capacity consent Exclusion Intolerance failure respond one treatments Diagnoses schizoaffective disorder , mental retardation , pervasive developmental disorder , delirium , dementia , amnesia First episode schizophrenia Women currently pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Antipsychotic Treatment</keyword>
	<keyword>Effectiveness</keyword>
</DOC>